Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05471856 · ClinicalTrials.gov registry record · Phase 1

A Study to Test How Different Doses of BI 1703880 in Combination With Ezabenlimab Are Tolerated in People With Different Types of Advanced Cancer (Solid Tumours)

A Phase 1 study of Solid Tumors, sponsored by Boehringer Ingelheim.

Recruiting
Registry status
Phase 1
Development phase
66
Enrollment target
13
Study locations

NCT05471856 is a Phase 1 study of Solid Tumors that is actively recruiting participants, run by Boehringer Ingelheim. The registered enrollment target is 66 participants, below the 284-participant average among 125 other Solid Tumors trials with a reported enrollment target (77% lower). The trial reports 13 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05471856, a Phase 1 study of Solid Tumors, is actively recruiting participants, sponsored by Boehringer Ingelheim.

RECRUITING
Registry status
Phase 1
Development phase
66 participants
Enrollment target
13
Study locations

Study Summary

This study is open to adults with different types of advanced cancer. People can take part if previous treatment was not successful, or no treatment exists. The purpose of this study is to find the highest dose of a medicine called BI 1703880 that people with advanced cancer can tolerate when taken together with ezabenlimab. BI 1703880 and ezabenlimab are medicines that may help the immune system fight cancer. In this study, BI 1703880 is given to people for the first time. Participants get BI 1703880 and ezabenlimab as infusions into a vein. During the first 6 weeks, they get BI 1703880 once a week. Later, they get BI 1703880 every 3 weeks. After the first 3 weeks, they get ezabenlimab in addition every 3 weeks. Participants can get BI 1703880 for up to 1 year and ezabenlimab for up to 2 years as long as they benefit from treatment and can tolerate it. During this time, they visit the study site regularly. At these visits, the doctors check participants' health and take note of any unwanted effects.

Conditions Studied

Solid Tumors

Interventions

  • DRUG BI 1703880
  • DRUG Ezabenlimab

Study Locations (13)

Other

  • National Cancer Center Hospital East - Chiba, Kashiwa
  • Saitama Medical University International Medical Center - Saitama, Hidaka
  • Japanese Foundation for Cancer Research - Tokyo, Koto-ku
  • Hospital Universitari Vall D Hebron - Barcelona
  • CIO Clara Campal - Madrid
  • Instituto Valenciano de Oncología - Valencia
  • Hospital Clinico Universitario De Valencia - Valencia
  • The Royal Marsden Hospital, Chelsea - London
  • Churchill Hospital - Oxford
  • The Royal Marsden Hospital, Sutton - Sutton

California

  • Valkyrie Clinical Trials - Los Angeles

Connecticut

  • Yale University School of Medicine - New Haven

New Jersey

  • John Theurer Cancer Center - Hackensack

Trial Details

FieldValue
Enrollment Target 66 participants
Start Date 2023-02-24
Est. Completion 2028-09-13
Phase Phase 1

Sponsor

Boehringer Ingelheim

515 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05471856

The ClinicalTrials.gov registry entry for NCT05471856 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 284-participant average among 125 other Solid Tumors trials with a reported enrollment target (77% lower). The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Solid Tumors appearing as the primary indexed condition, and to 2 interventions - of which BI 1703880 is the first listed.

NCT05471856 reports 13 study locations spanning 4 distinct geographic areas - top geographies include Other, California, Connecticut.

Frequently Asked Questions

What is clinical trial NCT05471856 about?

NCT05471856 is a clinical study titled "A Study to Test How Different Doses of BI 1703880 in Combination With Ezabenlimab Are Tolerated in People With Different Types of Advanced Cancer (Solid Tumours)". This study is open to adults with different types of advanced cancer. People can take part if previous treatment was not successful, or no treatment exists. The purpose of this study is to find the highest dose of a medicine called BI 1703880 that people with advanced cancer can tolerate when taken...

What is the current status of trial NCT05471856?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 66 participants. The study started on 2023-02-24. Estimated completion is 2028-09-13.

What conditions does trial NCT05471856 study?

This clinical trial studies the following conditions: Solid Tumors.

What interventions are being tested in trial NCT05471856?

The interventions under investigation include: BI 1703880 (DRUG), Ezabenlimab (DRUG).

Who is sponsoring clinical trial NCT05471856?

This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05471856 being conducted?

This trial has 13 study locations across California, Connecticut, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Solid Tumors

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Solid Tumors

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.